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• A continuous Markov model is used to assess whether disability progression on each of the DMTs is consistent with a cost effectiveness target of £36,000 per quality-adjusted life-year (QALY) projected over 20 years (as stipulated at the outset of the Scheme)
• Projections are made with the model using natural history data from the British Columbia Multiple Sclerosis database (BCMS) and hazard ratios (HRs) for attenuated disability progression, as measured by Expanded Disability Status Scale (EDSS) score, derived from the individual randomised controlled trials (RCTs) of each drug
• Actual disability progression was monitored in a cohort of 5,600 patients, with the intention of making price adjustments to maintain cost effectiveness should their progress differ substantially from the projections -The comparator cohort used patient data from the BCMS database who met the same eligibility criteria (data collection 1980-1996) • Primary outcomes were HRs (treated vs untreated) for accumulation of disability measured both as EDSS progression and as loss of utility -A ratio of less than 100% for EDSS implied slower than expected progression on treatment with GA compared to the untreated cohort
• Cost effectiveness of GA was expressed in two different ways:
-The HR for EDSS progression was compared to a target HR derived from the RCTs of GA, with a prespecified deviation of 10% about this target set, above or below which the price of GA would decrease or increase, respectively -The HR for EDSS progression was input into the cost-effectiveness calculator part of the model to determine whether the cost per QALY, based on a cost of GA per annum of £5,823 set at the inception of the scheme, 1 was above or below the £36,000 target
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• 978 patients starting GA and 898 comparator patients were included in the analyses (Table 1) • The cohorts had broadly similar baseline characteristics, although the GA cohort was older at disease onset (median 30 vs 28 years, respectively) and had a higher EDSS at baseline (median 3 vs 2) than the BCMS cohort
• This 6-year analysis supports the long-term efficacy of GA in terms of disability in patients with relapsing MS
• GA was shown to be more cost effective than predicted at the outset of the RSS, when modelled using the 6-year data over a 20-year time horizon
• Further insights into the long-term benefits of GA will come from the forthcoming analyses of the 8-and 10-year RSS data • The authors would like to thank Dr Jacqueline Palace (Oxford University Hospitals Trust, Oxford, UK) and Dr Martin Duddy (Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK) for reviewing the abstract prior to submission • The model showed a 30.3% reduction in EDSS progression (HR 69.7) with GA therapy vs no treatment (Figure 2 ), which exceeded the target HR for cost effectiveness by over 10%
• GA therapy was also shown to reduce utility loss by 55.8% (HR 44.2) vs no treatment
• In absolute terms, patients who received GA had a mean EDSS score that was 0·404 units less than would have occurred without therapy (as predicted by the model)
• The resultant cost per QALY for GA was well below the target of £36,000 A ratio of less than 100% for EDSS implies slower than expected progression on DMT treatment compared to the untreated cohort. A utility progression ratio of 62% or lower means that utility progression for the drugs in aggregate is in line with, or slower than, the target cost effectiveness
• To assess the clinical-and cost-effectiveness of GA, in terms of disability progression, using 6-year data from the RSS OBJECTIVE
